Floatz logo

Babaodan

Primary Biliary Cholangitis

Mei HanPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Primary Biliary Cholangitis cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Xijing Hospital of Digestive Diseases
Phase 4A
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
Fenofibrate
Xijing Hospital of Digestive Diseases
Phase 3BB
cs0159
Cascade Pharmaceuticals, Inc
Phase 3BB
Obeticholic Acid
Intercept Pharmaceuticals
Phase 3BB

View all 50 →

Same molecule, other indications

Babaodan is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
56 / 100
View asset →
Radiation PneumonitisDormant
CCC
Indicative ·
53 / 100
View asset →
chronic hepatitis B virus infectionDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →